A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

BACKGROUND: Dupilumab has demonstrated efficacy and acceptable safety in adults and children (aged 6–17 years) with moderate‐to‐severe atopic dermatitis (AD), but effective systemic therapy with a favorable risk–benefit profile in younger children remains a significant unmet need. OBJECTIVES: To det...

Descripción completa

Detalles Bibliográficos
Autores principales: Paller, A.S., Siegfried, E.C., Simpson, E.L., Cork, M.J., Lockshin, B., Kosloski, M.P., Kamal, M.A., Davis, J.D., Sun, X., Pirozzi, G., Graham, N.M.H., Gadkari, A., Eckert, L., Ruddy, M., Bansal, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Allergy and Eczema
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894166/
https://www.ncbi.nlm.nih.gov/pubmed/32893393
http://dx.doi.org/10.1111/jdv.16928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894166/
https://www.ncbi.nlm.nih.gov/pubmed/32893393
http://dx.doi.org/10.1111/jdv.16928

Ejemplares similares